Introduction to Planning for Outcomes (P4O) Model Webinar

Some observational studies have raised concerns about a possible link between the use of progestogen-only injectable contraceptives, particularly depot medroxyprogesterone acetate (DMPA), and the risk of HIV acquisition. The ongoing Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial is comparing DMPA, levonorgestrel implants, and copper intrauterine device (IUD) use on risk of HIV acquisition among women in four African countries, with results expected in 2019. Depending on the evidence obtained from the ECHO trial, injectable use could be reduced in countries with high HIV burden. P4O was developed to help officials in countries be able to assess how restrictions on DMPA use could affect HIV and maternal and child health outcomes and what it might take to compensate for such restrictions.

P4O was developed by FHI 360 in collaboration with USAID under the USAID-funded Envision FP project.